preludedx dcisionrt logo

How does the DCISionRT test benefit me?

The DCISionRT® test indicates your individual risk of recurrence and expected benefit from radiation therapy. This allows you and your physician to formulate a personalized treatment plan using your underlying DCIS biology.

The information provided by DCISionRT can help your physician to better balance the benefit of a treatment with the risk of side-effects.

DCISionRT empowers women with information about their biological risk profile. Before you make a decision, Know Your Risk™

Contact Us

The Most Accurate Test for DCIS

Accurate Test mobile image

The DCISionRT test quantifies the risk of your DCIS coming back (recurring) as well as predicting whether radiation therapy will benefit you.

FAQs

DCISionRT is a risk assessment test for patients with ductal carcinoma in situ (DCIS). The test was developed by PreludeDx and built on research that began with funding from the National Cancer Institute to better understand the biology of DCIS. DCISionRT assesses a patient’s individual biology along with other risk factors to provide a personalized assessment that predicts the risk of your DCIS coming back (recurring) over the next 10 years. The test calculates a personalized recurrence score and identifies your risk as low or elevated. DCISionRT provides information that may help you and your physician make a more informed treatment decision.

The DCISionRT test can be an important part of your doctor’s effort to evaluate your specific health needs and recommend the most appropriate treatment for your DCIS. By evaluating seven different biomarkers as well as other risk factors, DCISionRT provides the insight needed to better understand your risk of DCIS recurrence. Based upon your personalized results, the test allows you and your physician to make a decision whether surgery alone or surgery with radiation is appropriate.
DCISionRT should be ordered after initial diagnosis to accurately assess your risk. After your breast care physician receives the DCISionRT test report, he/she will then sit down with you to discuss your results and personalized treatment plan.
DCISionRT is easily ordered by your breast care doctor. An order request can simply be faxed by your doctor’s office to PreludeDx. Our Care Team will take care of locating your original biopsy or surgical specimen and provide results to your doctor within 2-3 days from receipt—no additional biopsy or surgery is required.

PreludeDx is leading the way with unsurpassed turnaround time and provides results in as little as 3-5 days from receiving your specimen. We understand the anxiety associated with uncertainty and strive to get you results quickly so that you and your doctor can make an informed decision.

PreludeDx currently accepts all insurance plans. As with all healthcare, your insurance may include a deductible, co-insurance or co-pay amount depending on your individual plan. PreludeDx is sensitive to all patient needs and offers a variety of financial assistance programs. Contact our Patient Care Team, at 888.211.3247 for more information.

DCISionRT is the latest innovation for DCIS patients. Physicians across the country, including the top US cancer centers use DCISionRT in their treatment planning. If you have questions about discussing this new test with your doctor, please contact our Customer Care team at 888.211.3247.

If you are interested in speaking with a patient advocate, please contact our Customer Care Team at 888.211.3247.

Case Studies

The DCISionRT® test indicates your individual risk of recurrence and expected benefit from radiation therapy.

Example 1

Age: 54 years  |  DCIS Grade: High (Grade 3)  |  DCIS size: 12mm

Before DCISionRT

Risk Assessment
Traditional Clinpath Features

TREATMENT PLAN:
Surgery with radiation therapy

TREATMENT RATIONALE:
Radiation therapy after breast conserving surgery is recommended based on presence of high grade (grade 3) DCIS.

After DCISionRT

Risk Assessment

TREATMENT PLAN:
Breast conserving surgery

TREATMENT RATIONALE:
Because the patient has a Low DCISionRT score, the Physician and patient decide to defer radiation therapy and elect breast conserving surgery in order to preserve the option for radiation therapy should the patient have a recurrence in the future.

Example 2

Age: 65 years  |  DCIS Grade: Low (Grade 1)  |  DCIS size: 6mm

Before DCISionRT

Risk Assessment
Traditional Clinpath Features

TREATMENT PLAN:
Breast conserving surgery

TREATMENT RATIONALE:
Traditional risk assessment using clinicopathologic features indicates patient could be considered “low risk” and therefore, the patient and physician elect to forego radiation therapy.

dcisionrt example 2 graph

After DCISionRT

Risk Assessment

TREATMENT PLAN:
Surgery with radiation therapy

TREATMENT RATIONALE:
New information from DCISionRT indicates the patient is at Elevated Risk if treated with surgery alone. The patient and physician decide to use radiation therapy-–despite traditionally low risk clinicopathalogic features—due to the large risk reduction from radiation therapy.

Insurance

  • PreludeDx accepts all insurance plans
  • Financial assistance may be available for patients meeting certain requirements (contact Customer Care for details)